Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
Medtronic
Moodys
Colorcon

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR XIFAXAN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Xifaxan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00269399 ↗ A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Completed Bausch Health Americas, Inc. Phase 3 2005-12-01 The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD).
NCT00269399 ↗ A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Completed Valeant Pharmaceuticals International, Inc. Phase 3 2005-12-01 The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD).
NCT00577772 ↗ Transit Time and Bacterial Overgrowth Using SmartPill Capsule Terminated The SmartPill Corporation N/A 2007-11-01 The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test. Additionally, the ability of the SmartPill GI Monitoring System to discriminate between healthy human subjects and patients with small bowel bacterial overgrowth will be explored using analyses of both pH and pressure patterns within the stomach and small intestine. The study will be performed in both normal subjects and patients with and without small bowel bacterial overgrowth.
NCT00577772 ↗ Transit Time and Bacterial Overgrowth Using SmartPill Capsule Terminated Mayo Clinic N/A 2007-11-01 The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test. Additionally, the ability of the SmartPill GI Monitoring System to discriminate between healthy human subjects and patients with small bowel bacterial overgrowth will be explored using analyses of both pH and pressure patterns within the stomach and small intestine. The study will be performed in both normal subjects and patients with and without small bowel bacterial overgrowth.
NCT00603616 ↗ Induction of Clinical Response Using Rifaximin in Crohn's Disease Completed Bausch Health Americas, Inc. Phase 2 2008-11-01 Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease.
NCT00603616 ↗ Induction of Clinical Response Using Rifaximin in Crohn's Disease Completed Valeant Pharmaceuticals International, Inc. Phase 2 2008-11-01 Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease.
NCT00603616 ↗ Induction of Clinical Response Using Rifaximin in Crohn's Disease Completed Scott Lee Phase 2 2008-11-01 Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xifaxan

Condition Name

Condition Name for Xifaxan
Intervention Trials
Small Intestinal Bacterial Overgrowth 4
Cirrhosis 4
Irritable Bowel Syndrome 3
Hepatic Encephalopathy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Xifaxan
Intervention Trials
Diarrhea 7
Hepatic Encephalopathy 5
Brain Diseases 5
Syndrome 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Xifaxan

Trials by Country

Trials by Country for Xifaxan
Location Trials
United States 83
China 3
Germany 2
Norway 2
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Xifaxan
Location Trials
California 9
Florida 6
Arizona 4
Texas 4
Georgia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Xifaxan

Clinical Trial Phase

Clinical Trial Phase for Xifaxan
Clinical Trial Phase Trials
Phase 4 7
Phase 3 6
Phase 2 10
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Xifaxan
Clinical Trial Phase Trials
Completed 19
Terminated 5
Recruiting 5
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Xifaxan

Sponsor Name

Sponsor Name for Xifaxan
Sponsor Trials
Bausch Health Americas, Inc. 8
Valeant Pharmaceuticals International, Inc. 8
Mayo Clinic 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Xifaxan
Sponsor Trials
Other 47
Industry 21
U.S. Fed 7
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Mallinckrodt
Boehringer Ingelheim
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.